Aurobindo Pharma receives USFDA approval for Extended Phenytoin Sodium Capsules

15 Jun 2015 Evaluate

Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Extended Phenytoin Sodium Capsules USP, 100mg (ANDA 204309). The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Dilantin of Parke-Davis Division of Pfizer Inc.

Phenytoin Sodium Extended Capsules is an anti-epileptic product and indicated for the control of seizures and prevention and treatment of seizures occurring during or following neurosurgery. The product has an estimated market size of USD125 Million for the twelve months ending April 2015 according to IMS.

This is the 38th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products. Aurobindo now has a total of 199 ANDA approvals (172 Final approvals including 9 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1181.00 -4.50 (-0.38%)
16-Dec-2025 11:24 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1787.30
Dr. Reddys Lab 1276.40
Cipla 1506.35
Zydus Lifesciences 920.50
Lupin 2088.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×